What We Have Done

What We Have Done 2017-10-13T09:40:33-04:00


Cabernet Pharmaceuticals has assembled scientists and project managers with deep experience in applying pharmacogenetics (PGx) to all phases of drug development and to drug discovery as well. Previously, they conceived and executed PGx studies while holding direct or collaborative roles at large pharmaceutical corporations, biotechnology companies, and academic research institutions. Now they continue that pioneering work within the consultancy network of Cabernet and its sister company, Zinfandel Pharmaceuticals.

Our staff have consulted for or collaborated with partners in pharma (Eli Lilly and Company; Merck; Takeda Pharmaceutical Company Limited; Astellas Pharma US, Inc.; Daiichi-Sankyo Company, Limited), biotechs (Cancer Guide Diagnostics, Nebbiolo Technologies), and academia (Duke University, Northwestern University, Rush University, University of Ottawa Heart Institute, Murdoch University, Perron Institute for Neurological and Translational Science).

Examples of their contributions appear below.

Late Development –
Marketed Products


Early Development –
Proof of Concept

Opioid-receptor antagonist
CCK-A receptor agonist


Alzheimer’s Disease Risk Biomarker